Clinical Studies

CABERNET

This is the company’s first pivotal study, which completed enrollment in October, 2009. The CABERNET Study was conducted in 41 countries throughout the world, with 494 subjects enrolled.

The objective of the CABERNET Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration (AMD). Initial data from this landmark study will be released in Q1, 2012.